Identify and select optimal T cell phenotypes

Cell & Gene Therapy Insights 2021; 7(1), 81.

10.18609/cgti.2021.046

Published: 22 February 2021
FastFacts
James Lovrgen


Watch the video or read the poster to learn:

  • What are the key challenges facing adoptive cell therapy developers?
  • How can we identify the best T cells for adoptive therapies?
  • How can multidimensional, functional assays on single T cells help develop powerful and effective therapies?

About the speaker

James Lovrgen is an accomplished life science execute with a distinguished track record of commercializing disruptive technologies and managing industry-leading global product portfolios. He currently serves as the VP of Cell Therapy Marketing of Berkeley Lights where he leads the development and execution of the company's marketing and product development strategy. Most recently, he served as the General Manager of Cell and Gene Therapy at Thermo Fisher Scientific. James holds as BS in Biology from University of North Florida and an MBA from North Carolina State University. 


View pdf




We hope you enjoyed this FastFacts video. You can also view the summary PDF here..




This article is part of the Preclinical/translational tools and strategies spotlight